Aon appoints Andy Marcell to serve as CEO of Global Solutions
DUBLIN, June 2, 2025 /PRNewswire/ -- Aon plc (NYSE: AON), a leading global…
MFS Announces Closed-End Fund Distributions
BOSTON--(BUSINESS WIRE)--MFS Investment Management® (MFS®) announced today monthly distributions of the following…
KKR to Present at the Morgan Stanley US Financials Conference 2025
NEW YORK--(BUSINESS WIRE)--KKR & Co. Inc. (NYSE: KKR) announced today that Adam…
HOTEL101 PROGRESSES TOWARDS NASDAQ LISTING
U.S. SEC DECLARES FORM F-4 SEC REGISTRATION EFFECTIVE SINGAPORE, June 2, 2025…
Kia Announces May 2025 Global Sales Results
May 2025 global sales of 269,148 units, up 1.7% Y/yOutside of Korea,…
Novartis Pluvicto demonstrates statistically significant and clinically meaningful rPFS benefit in patients with PSMA-positive metastatic hormone-sensitive prostate cancer
Ad hoc announcement pursuant to Art. 53 LR At interim analysis, PSMAddition…
![Sandoz launches first and only interchangeable denosumab biosimilars in US, providing new affordable treatment options for over 10 million patients[1]](https://i0.wp.com/ml-eu.globenewswire.com/media/NjEzMmQ4NzAtZTBkMS00ZDhhLTkyYjgtOGM3YzY1ZWM5M2U5LTEwMTQyODItMjAyNS0wNi0wMi1lbg==/tiny/Sandoz-International-GmbH.png?w=420&resize=420,280&ssl=1 "Sandoz launches first and only interchangeable denosumab biosimilars in US, providing new affordable treatment options for over 10 million patients[1]")
Sandoz launches first and only interchangeable denosumab biosimilars in US, providing new affordable treatment options for over 10 million patients[1]
Ad-hoc announcement pursuant to art. 53 SIX Swiss Exchange Listing Rules MEDIA…
Vodafone Qatar selects Nokia in major network modernization deal to drive expanded 5G coverage, reliability, and services
Press ReleaseVodafone Qatar selects Nokia in major network modernization deal to drive…
JAMining Expands FCA-Regulated Cloud Mining Services Amid Surging Crypto Market Activity
Image by JAMining LONDON, May 31, 2025 (GLOBE NEWSWIRE) -- JAMining, a…
New data show Roches Itovebi significantly extended survival in a certain type of HR-positive advanced breast cancer
The ItovebiTM (inavolisib)-based regimen reduced the risk of death by more than…